Verapamil Effect in Cystic Fibrosis-related Dysglycemia
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age14+
SponsorRhode Island Hospital
About this trial
The investigators are conducting a pilot open-label pre/post interventional trial in adolescents and adults with cystic fibrosis (CF) and abnormal glucose tolerance or early CF-related diabetes mellitus (CFRD) to assess the safety and efficacy of verapamil on beta cell function and dysglycemia.
Eligibility criteria
Qualifiers
Age 14 years and older
Genetically-confirmed diagnosis of cystic fibrosis
Clinical diagnosis of pancreatic insufficiency, defined as requiring pancreatic enzyme replacement therapy (PERT)
Diagnosis of AGT or CFRD within 3-months of study enrollment
Disqualifiers
Severe lung disease indicated by forced expiratory volume in 1 second (FEV1) <50% predicted on most recent spirometry testing
Body mass index (BMI) <18 kg/m2
Weight <50 kg
Current or planned pregnancy within the next 6 months
Trial design
Treatments tested in this trial
- Verapamil Hydrochloride
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov